News from the life sciences community north of Boston
July 2022
Nestlé Health Science has recently focused on acquisitions and partnerships relating to food allergies, gut health, and the microbiome. In its latest move announced today, Nestlé has invested $41 million in a strategic R&D collaboration with Enterome, a Paris-based clinical stage biopharmaceutical company. The partnership will advance the development and commercialization of new immunotherapies for food allergies and inflammatory bowel disease. Last year, Nestlé entered into a joint commercialization agreement with Seres Therapeutics of Cambridge to develop a microbiome therapeutic. Read more in Fierce Biotech.
Sunflower Therapeutics, a Public Benefit Corporation, is a unique biotech company with a mission to enable more medicines to reach patients. The company's goal is to transform access to biologic medicines for patients worldwide by creating novel technologies for development and manufacturing with the global community in mind. Sunflower's 4,100 SF lab and office at 200 Boston Avenue, Medford, is being designed and constructed by Cummings' in-house team. Kerry R. Love, Ph.D., is Sunflower's CEO and president.
Myro Therapeutics will also soon occupy a 4,400 SF lab and office suite at 200 Boston Avenue. The company is working to develop first-in-class and best-in-class small molecule drugs for neuroimmune, demyelinating, neurodegenerative, and neuropsychiatric disorders. Jing Wang, Ph.D., is Myro Therapeutics' co-founder and CEO.
Congratulations to Vaxess Technologies, recently featured in an interview with Cheddar News. Vaxess co-founder and CEO Michael Schrader discussed how the company's innovative technology can become the future of needle-free vaccines. The MIMIX smart release intradermal patch can enable distribution of self-administered vaccines globally without need for refrigeration or requiring administration by a health care professional. Vaxess recently expanded its GMP production facility at Cummings Park in Woburn.
"We think there's a future pathway here for a whole host of drugs that currently require trips to the doctor's office to be moved into the home."

Co-founder and CEO
A new article from Genetic Engineering & Biotechnology News features thoughts from Korro Bio CEO Ram Aiyar. The article details the potential the company sees in RNA editing, which avoids permanent changes to DNA. Korro Bio, headquartered in Cambridge with lab and office space at Cummings Park in Woburn, is an RNA-editing company focused on discovering and developing precision genetic medicines to treat a wide range of rare and prevalent diseases.
"We believe that our transient approach will offer functional cures to prevalent chronic patient populations, and that patients will be able to take an RNA-editing drug, like any other chronic disease drug, for the rest of their lives."

Korro Bio
The 15th annual Massachusetts Life Sciences Innovation (MALSI) Day is a major event for life sciences startups and innovation in the Commonwealth. The high-energy, hands-on, global program brings together scientific leaders and business experts to mingle with scientists, post-docs, professors, entrepreneurs, innovators, and venture capitalists.
The day features panel discussions, an emerging technology poster competition, Innovators' Marketplace, and a networking reception with leading life sciences CEOs. The program is the flagship event of life sciences in Massachusetts, put together by Innovation Studio in partnership with MassVentures, and major organizations involved in starting and supporting the life sciences startup ecosystem in the Commonwealth. Register.
The MassBio 2022 Diversity, Equity, and Inclusion Conference, an in-person and virtual event, will be held at the MassBio Hub. Thursday, July 21, from 1:00 to 6:00 PM. Register.
8 Cabot Road, Woburn
15,000 SF Office, Labs & R&D Suite
This full-floor suite in a first-class life sciences building located just off I-93 at the I-95 interchange, features lab, R&D, and large office space. Contact a Cummings lab specialist at or 781-983-7039 for details. Features include:
  • 4,000 SF Lab/R&D | 11,000 SF office
  • Bright windows and ample natural light
  • Open lab with two fume hoods
  • R&D/manufacturing space
  • Large break room
From Lord & Taylor to Lab Coats:
Burlington Mall Retailer to Become Lab Space
Further proof of the strength of the life sciences industry in MetroNorth and the region's insatiable appetite for lab space, the real estate arm of retail holding company Hudson's Bay Co. plans to convert a former Burlington Mall department store to lab space. Catherine Carlock of The Boston Globe reports on the latest in a string of recent conversions.
Have news to share? Please let us know! We are interested in company news, personnel changes, product launches, funding updates, events, and more. Contact Sue Howland, client engagement manager, at to share your news for upcoming newsletters. We look forward to hearing from you.
Keep up with news from the Cummings community by following us on LinkedInFacebookTwitter, and Instagram.